StemCell Therapy

DUBLIN, Jan. 3, 2020 /PRNewswire/ -- The "The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of microbiome-based medical products (including therapeutics, diagnostics and FMTs), over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for microbiome therapeutics, diagnostics and FMTs, over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends based on the sales of approved / late stage (estimated) microbiome therapeutics, diagnostic products and FMTs.

The report also features the likely distribution of the current and forecasted opportunity within microbiome therapeutics market across:

In addition, it also features the likely distribution of the current and forecasted opportunity within microbiome diagnostics market across:

In addition to other elements, the study includes:

In order to account for the uncertainties associated with the growth of microbiome market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Key Topics Covered

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Chapter Overview3.2. Concept of Microbiota and Microbiome3.3. Overview of Gut Flora3.4. The Microbiome and Disease3.5. Impact of Microbiota on Drug Pharmacokinetics3.6. Impact of Microbiota on Therapeutic Outcomes3.7. Microbiome Therapeutics3.8. The Human Microbiome Project (HMP)3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)3.10. Key Challenges in the Development of Microbiome Therapeutics3.11. Future Perspectives

4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE4.1. Chapter Overview4.2. Microbiome Therapeutics: Clinical Pipeline4.3. Microbiome Therapeutics: Early-Stage Pipeline4.4. Microbiome Therapeutics: List of Drug Developers4.5. Microbiome Therapeutics: List of Discontinued Drugs4.6. Emerging Role of Microbiome in Gut-Brain Axis4.7. Microbiome Therapeutics: List of Technology Platforms

5. COMPANY AND DRUG PROFILES5.1. Chapter Overview5.2. 4D Pharma5.3. Armata Pharmaceuticals5.4. Evelo Biosciences5.5. Rebiotix (Acquired by Ferring Pharmaceuticals)5.6. Seres Therapeutics5.7. Vedanta Biosciences

6. MICROBIOME DIAGNOSTICS: MARKET LANDSCAPE6.1. Chapter Overview6.2. Overview of Microbiome Diagnostic Tests6.3. Microbiome Diagnostic Tests: Marketed and Under Development Products6.4. Microbiome Diagnostic Tests: List of Diagnostic Developers6.5. Profiles of Prominent Diagnostic Developers6.6. Overview of Microbiome Screening / Profiling Tests

7. FECAL MICROBIOTA THERAPY (FMT)7.1. Chapter Overview7.2. Introduction to FMT7.3. Historical Overview7.4. FMT: Procedure and Clinical Relevance7.5. Regulatory Guidelines Related to FMT7.6. Insurance Coverage for FMT7.7. FMT: Competitive Landscape7.8. Clinical Trial Analysis (Non-Industry Sponsored)7.9. Stool Banks

8. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX8.1. Chapter Overview8.2. AC Matrix: An Overview8.3. AC Matrix: Analytical Methodology8.4. AC Matrix: Plotting the Information8.5. AC Matrix: Analyzing the Data8.6. Concluding Remarks

9. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS9.1. Chapter Overview9.2. Scope and Methodology9.3. Initiatives of Big Pharmaceutical Players9.4. Benchmark Analysis of Big Pharmaceutical Players

10. START-UP HEALTH INDEXING10.1. Chapter Overview10.2. Scope and Methodology10.3. Benchmark Analysis of Start-ups

11. KEY THERAPEUTIC AREAS11.1. Chapter Overview11.2. Metabolic Disorders11.3. Digestive and Gastrointestinal Disorders11.4. Oncological Indications11.5. Dermatological Disorders11.6. Infectious Diseases

12. FUNDING AND INVESTMENT ANALYSIS12.1. Chapter Overview12.2. Types of Funding12.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments12.4. Concluding Remarks

13. CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS13.1. Chapter Overview13.2. Manufacturing Microbiome Therapeutics13.3. Microbiome Therapeutics-related R&D13.4. Key Considerations for Selecting a Suitable CMO / CRO Partner

14. BIG DATA AND MICROBIOME THERAPEUTICS14.1. Chapter Overview14.2. Introduction to Big Data14.3. Internet of Things14.4. Growing Interest in Big Data: Google Trends Analysis14.5. Key Application Areas14.6. Big Data in Microbiome Research14.7. Big Data Services for Microbiome Research: List of Companies14.8. Big Data Services for Microbiome Research: Profiles of Key Players

15. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS15.1. Chapter Overview15.2. Scope and Limitations15.3. Forecast Methodology15.4. Overall Microbiome Therapeutics Market, 2019-203015.5. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2019-2030

16. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS16.1. Chapter Overview16.2. Scope and Limitations16.3 Forecast Methodology16.4. Overall Microbiome Diagnostics Market, 2019-203016.5. Microbiome Diagnostics Market: Distribution by Target Indications, 2019-203016.6. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019-203016.7. Microbiome Diagnostics Market: Distribution by Supply Channel, 2019-203016.8. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019-2030

17. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS17.1. Chapter Overview17.2. Scope and Limitations17.3. Forecast Methodology17.4. Overall FMT Market, 2019-203017.5. Overall Microbiome Market by Product Offerings, 2019-2030

18. CASE STUDY: MICROBIOME-BASED PRODUCTS IN OTHER INDUSTRIES18.1. Chapter Overview18.2. List of Microbiome Products in Other Industries18.3. Applications of Microbiome Based Products in Agriculture Industry18.4. Future Prospects

19. CONCLUDING REMARKS

20. EXECUTIVE INSIGHTS20.1 Chapter Overview20.2. Rebiotix20.3. S-Biomedic20.4. Whole Biome20.5. Siolta Therapeutics20.6. OpenBiome20.7 Assembly Biosciences20.8. List Biological Laboratories20.9. Metabiomics20.10. MicroBiome Therapeutics20.11. Universal Stabilization Technologies20.12. BiomX20.13. Da Volterra20.14. Chung Mei Pharmaceutical20.15. Pacific Northwest National Laboratories

21. APPENDIX I: TABULATED DATA

22. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/sakzqu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Continue reading here:
Global Human Microbiome Markets (2019-2030), Drugs, Companies, Therapeutics, Diagnostics, Case Studies, Executive Insights, and More - PRNewswire

This entry was posted on January 3, 2020 at 8:42 am and is filed under Molecular Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |